While clinicians often ponder how to prioritize treatments for patients with multiple actionable biomarkers, this scenario is exceedingly rare in practice. The guiding principle, if it does occur, is to choose the therapy with the strongest supporting clinical trial data, though this remains an infrequent dilemma.
The DYNAMIC trial disappointingly showed that intensifying adjuvant chemotherapy for high-risk, ctDNA-positive stage 3 colorectal cancer patients does not improve outcomes. This suggests that for these tumors, underlying biology dictates recurrence more strongly than the aggressiveness of chemotherapy.
To maximize the chances of successful biomarker identification from a liquid biopsy, especially when tissue is scant, the blood sample must be drawn before initiating any chemotherapy. This pre-treatment timing is critical for improving the diagnostic yield of blood-based next-generation sequencing (NGS) testing.
The frontline trial for the pan-RAS inhibitor Diraxon RAS-sib in pancreatic cancer is designed without biomarker pre-selection. This unique strategy is based on the premise that 95% of these cancers are RAS-mutated, and even the remaining 5% are likely RAS-driven, potentially broadening the eligible patient population.
Contrary to common belief, low biomarker testing rates (30-60%) are not just a community oncology problem; even academic medical centers are "guilty" of failing to test all eligible GI cancer patients. This highlights a systemic challenge in implementing personalized medicine, requiring proactive strategies at all levels of care.
The standard approach for first-line metastatic colorectal cancer is obsolete. Clinicians must test for and categorize patients into at least four, soon five, distinct biomarker-defined subgroups (MSI-high, BRAF V600E, RAS/RAF wild-type, HER2-positive, and the RAS-mutated "catch-all") to select the optimal initial therapy.